Li-Xia Peng

Li-Xia Peng

Auto-generated profile, based on publicly available information

Li-Xia Peng

Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
HYHong-Jie Yang
Hong-Jie Yang
THTie-Jun Huang
Tie-Jun Huang
CYChang-Fu Yang
Chang-Fu Yang
LPLi-Xia Peng
Li-Xia Peng
RLRan-yi Liu
Ran-yi Liu
BHBi-Jun Huang
Bi-Jun Huang
Background: Epstein-Barr virus (EBV) is an etiological cause of many human lymphocytic and epithelial malignancies. EBV expresses different genes that are associated with three latency types. To date, as many as 44 EBV-encoded miRNA species have been found, but their comprehensive profiles in the three types of latent infection that are associated with various types of tumors are not well documented. Methods: In the present study, we utilized poly (A)-tailed quantitative real-time RT-PCR in combination with microarray analysis to measure the relative abundances of viral miRNA species in a subset of representative lymphoid and epithelial tumor cells with various EBV latency types. Results: Our findings showed that the miR-BHRF1 and miR-BART families were expressed differentially in a tissue- and latency type-dependent manner. Specifically, in nasopharyngeal carcinoma (NPC) tissues and the EBV-positive cell line C666-1, the miR-BART family accounted for more than 10% of all detected miRNAs, suggesting that these miRNAs have important roles in maintaining latent EBV infections and in driving NPC tumorigenesis. In addition, EBV miRNA-based clustering analysis clearly distinguished between the three distinct EBV latency types, and our results suggested that a switch from type I to type III latency might occur in the Daudi BL cell line. Conclusions: Our data provide a comprehensive profiling of the EBV miRNA transcriptome that is associated with specific tumor cells in the three types of latent EBV infection states. EBV miRNA species represent a cluster of non-encoding latency biomarkers that are differentially expressed in tumor cells and may help to distinguish between the different latency types.

28 January 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DMDong-Fang Meng
Dong-Fang Meng
PXPing Xie
Ping Xie
LPLi-Xia Peng
Li-Xia Peng
RSRui Sun
Rui Sun
DLDong-Hua Luo
Dong-Hua Luo
CQChao-Nan Qian
Chao-Nan Qian
Nasopharyngeal carcinoma (NPC) is a common malignancy in Southern China and Southeast Asia. In this study, we investigated the functional and molecular mechanisms by which CDC42-interacting protein 4 (CIP4) influences NPC. The expression levels of CIP4 were examined by Western blot, qRT-PCR or IHC. MTT assay was used to detect the proliferative rate of NPC cells. The invasive abilities were examined by matrigel and transwell assay. The metastatic abilities of NPC cells were revealed in BALB/c nude mice. We report that CIP4 is required for NPC cell motility and invasion. CIP4 promotes the activation of N-WASP that controls invadopodia formation and activates EGFR signaling, which induces downstream MMP2 (matrix metalloproteinase 2) upregulation. In addition, CIP4 could promote NPC metastasis by activating the EGFR pathway. In nude mouse models, distant metastasis was significantly inhibited in CIP4-silenced groups. High CIP4 expression is an independent adverse prognostic factor of overall survival (OS) and distant metastasis-free survival (DMFS). We identify the critical role of CIP4 in metastasis of NPC which suggest that CIP4 may be a potential therapeutic target of NPC patients.

10 December 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ZCZhi-Yuan Chen
Zhi-Yuan Chen
MSMing Shi
Ming Shi
LPLi-Xia Peng
Li-Xia Peng
WWWei Wei
Wei Wei
XLXin-Jian Li
Xin-Jian Li
RGRong-ping Guo
Rong-ping Guo
Background: Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC). Method: In this study, we used five HCC cell lines and five endothelial cell lines to validate molecular and cellular targets of dovitinib. Results: Tumor growth and pulmonary metastasis were significantly suppressed in an orthotopic HCC model. Immunoblotting revealed that among known dovitinib targets, only PDGFR-β was expressed in two HCC cell lines, while four of five endothelial lines expressed PDGFR-β, FGFR-1, and VEGFR-2. Dovitinib inhibited endothelial cell proliferation and motility at 0.04 μmol/L, a pharmacologically relevant concentration; it was unable to inhibit the proliferation or motility of HCC cells at the same concentration. Immunohistochemical analyses showed that dovitinib significantly decreased the microvessel density of xenograft tumors, inhibiting proliferation and inducing apoptosis in HCC cells. Conclusion: Our findings indicate that dovitinib inhibits HCC growth and metastasis preferentially through an antiangiogenic mechanism, not through direct targeting of HCC cells.

3 April 2018 in Cancer Communications
Verified
Journal Article
Open access
PDF file
MYMeng‐Jie Yang
Meng‐Jie Yang
JGJie Guo
Jie Guo
YYYan‐Fang Ye
Yan‐Fang Ye
SCSui‐Hong Chen
Sui‐Hong Chen
LPLi‐Xia Peng
Li‐Xia Peng
SCSu-Mei Cao
Su-Mei Cao
Background: The association of circulating inflammation markers with nasopharyngeal carcinoma (NPC) is still largely unclear. This study aimed to comprehensively explore the relationship between circulating cytokine levels and the subsequent risk of NPC with a two‐stage epidemiologic study in southern China. Methods: The serum levels of 33 inflammatory cytokines were first measured in a hospital‐based case–control study (150 NPC patients and 150 controls) using multiplex assay platforms. Marker levels were categorized into two or more groups based on the proportion of sample measurements that was above the lower limit of detection. Odds ratios (ORs) and 95% confidence intervals (CIs) relating the serum marker concentration to the risk of NPC were computed by multivariable logistic regression models. The associations were validated in 60 patients with NPC and 120 controls in a subsequent nested case–control study within a NPC screening trial. Potential interactions between serum cytokines and Epstein–Barr virus (EBV) relating to the risk of NPC were assessed using a likelihood ratio test. Results: The levels of serum macrophage inflammatory protein (MIP)‐1α and MIP‐1β in the highest categories were associated with a decreased risk of NPC in both the case–control study (MIP‐1α: OR = 0.49, 95% CI = 0.26–0.95; MIP‐1β: OR = 0.47, 95% CI = 0.22–1.00) and the nested case–control study (MIP‐1α: OR = 0.13, 95% CI = 0.03–0.62; MIP‐1β: OR = 0.20, 95% CI = 0.04–0.94), compared with those in the lowest categories. Furthermore, individuals with lower levels of these two cytokine markers who were EBV seropositive presented with a largely higher risk of NPC compared with patients with higher levels who were EBV seronegative in both the case–control study (MIP‐1α: OR = 16.28, 95% CI = 7.11–37.23; MIP‐1β: OR = 12.86, 95% CI = 5.9–28.05) and the nested case–control study (MIP‐1α: OR = 86.12, 95% CI = 10.58–701.03; MIP‐1β: OR = 115.44, 95% CI = 13.92–957.73). Conclusions: Decreased preclinical MIP‐1α and MIP‐1β levels might be associated with a subsequently increased risk of NPC. More mechanistic studies are required to fully understand this finding.

27 March 2025 in Genes
Verified
Journal Article
Open access
PDF file
TGTianrui Gao
Tianrui Gao
MFMeiling Fan
Meiling Fan
ZZZhongyuan Zeng
Zhongyuan Zeng
LPLixia Peng
Lixia Peng
CQChao-Nan Qian
Chao-Nan Qian
BHBi-Jun Huang
Bi-Jun Huang
Background: RNA alternative splicing represents a pivotal regulatory mechanism of eukaryotic gene expression, wherein splicing factors (SFs) serve as key regulators. Aberrant SF expression drives oncogenic splice variant production, thereby promoting tumorigenesis and malignant progression. However, the biological functions and potential targets of SFs remain largely underexplored. Methods: Through multi-omics analysis, we identified survival-related splicing factors (SFs) in esophageal cancer and elucidated their biological regulatory networks. To further investigate their downstream splicing targets, we combined alternative splicing events resulting from SF knockdown with those specific to esophageal cancer. Finally, these splicing events were validated through full-length RNA sequencing and confirmed in cancer cells and clinical specimens. Result: We identified six SFs that are highly expressed in esophageal cancer and correlate with poor prognosis. Further analysis revealed that these factors are significantly associated with immune infiltration, cancer stemness, tumor heterogeneity, and drug resistance. CRNKL1 was identified as a hub SFs. The target genes and pathways regulated by these SFs showed substantial overlap, suggesting their coordinated roles in promoting cancer stemness and metastasis. Specifically, alternative splicing of key markers, such as CD44 and CTTN, was regulated by most of these SFs and correlated with poor prognosis. Conclusions: Our study unveils six survival-related SFs that contribute to the aggressiveness of esophageal cancer and CTTN and CD44 alternative splicing may act as common downstream effectors of survival-related SFs. This study provides mechanistic insights into SF-mediated tumorigenesis and highlight novel therapeutic vulnerabilities in esophageal cancer.